Technology Appraisal Guidance No. 243 (review of technology appraisal guidance 110)
Source: National Institute for Health and Care Excellence
NOTE: This guidance replaces Technology Appraisal Guidance No. 110 issued in September 2006.
1.1 Rituximab, in combination with:
- cyclophosphamide, vincristine and prednisolone (CVP)
- cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)
- mitoxantrone, chlorambucil and prednisolone (MCP)
- cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-a (CHVPi) or
is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated people.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA243
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: email@example.com
Rituximab for the First-Line Treatment of Stage III-IV Follicular Lymphoma.
Issue Date: January 2012